BiotechTube

nanomicellular cyclosporine 0.09% + Lifitegrast

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Dry Eye

Conditions

Dry Eye

Trial Timeline

Feb 1, 2020 → Dec 1, 2022

NCT ID
NCT04172961

About nanomicellular cyclosporine 0.09% + Lifitegrast

nanomicellular cyclosporine 0.09% + Lifitegrast is a approved stage product being developed by Sun Pharmaceutical for Dry Eye. The current trial status is unknown. This product is registered under clinical trial identifier NCT04172961. Target conditions include Dry Eye.

What happened to similar drugs?

17 of 20 similar drugs in Dry Eye were approved

Approved (17) Terminated (4) Active (3)
✅CequaTM (Cyclosporine 0.09%) ophthalmic solutionSun PharmaceuticalApproved
✅Cyclosporine + Artificial tearSun PharmaceuticalApproved
✅Cyclosporine 0.09% Ophthalmic SolutionSun PharmaceuticalApproved
✅Hydroxypropylmethylcellulose + CarboxymethylcelluloseMerckApproved
✅azithromycin ophthalmic solution, 1% + Visine® for Contacts®MerckApproved
✅Azithromycin Ophthalmic Solution, 1% + PlaceboMerckApproved
✅Lifitegrast 5% Ophthalmic SolutionNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04172961ApprovedUNKNOWN

Competing Products

20 competing products in Dry Eye

See all competitors
ProductCompanyStageHype Score
Cyclosporine Ophthalmic 0.05% Ophthalmic EmulsionSight SciencesPre-clinical
16
OK-101 + PlaceboOKYO PharmaPhase 2
25
ISV 101Sun PharmaceuticalPhase 2
27
CequaTM (Cyclosporine 0.09%) ophthalmic solutionSun PharmaceuticalApproved
43
0.09% cyclosporine A ophthalmic solutionSun PharmaceuticalPre-clinical
26
Cyclosporine + Artificial tearSun PharmaceuticalApproved
35
Cyclosporine 0.09% Ophthalmic SolutionSun PharmaceuticalApproved
43
Investigational Lubricating Eye Drop in a Novelia® bottle + Blink® Tears eye DropsJohnson & JohnsonPhase 2
35
diquafosol ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution.Santen PharmaceuticalPre-clinical
26
Diquafosol sodium 3% + Sodium hyaluronate 0.1%Santen PharmaceuticalPhase 2
31
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionSanten PharmaceuticalPhase 3
40
Placebo ophthalmic solution and 3% DE-089 ophthalmic solutionSanten PharmaceuticalPhase 1
29
DE-089 ophthalmic solution + DE-089 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
SHR8028 eye drops + Vehicle eye drops.Jiangsu Hengrui MedicinePhase 3
40
SHR8058 eye drops + saline eye drops.Jiangsu Hengrui MedicinePhase 3
40
ABBV-444 + REFRESH OPTIVE UDAbbViePhase 3
47
AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic SolutionAbbViePhase 1/2
32
ABBV-444AbbViePhase 3
40
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)AbbViePre-clinical
26
ABBV-319AbbViePhase 1
36